In the pivotal trastuzumab trial H0648g, 143 patients with metastatic HER2‐positive breast cancer received the trastuzumab/anthracycline combination and the incidence of symptomatic heart failure in the trastuzumab/anthracycline arm was 27%, with majority of patients receiving doxorubicin.3 The gene discussed is ERBB2; the disease is breast carcinoma.